Literature DB >> 10864599

Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis.

F Fazekas1, S Strasser-Fuchs, H Schmidt, C Enzinger, S Ropele, A Lechner, E Flooh, R Schmidt, H P Hartung.   

Abstract

OBJECTIVES: Clinical reports have speculated on a more severe course of multiple sclerosis in patients with the apolipoprotein E (apoE) epsilon4 allele. As this could be reflected by differences in the severity of tissue damage MRI was used to obtain further support for a disease modifying effect of the apoE genotype.
METHODS: Brain MR scans of 83 patients (mean age 35.5 (SD 9.5 years) who participated in a cross sectional study on the distribution of genotype patterns in multiple sclerosis. The total lesion load on proton density weighted (T2-LL) and T1 weighted scans (T1-LL) obtained with conventional spin echo sequences at 1.5 T was measured. A "black hole" ratio ((T1-LL/T2-LL)x100) was also calculated. This indicates the proportion of multiple sclerosis lesions with more severe tissue damage and may reflect disease aggressiveness or quality of repair.
RESULTS: Patients with the apoE-epsilon3/epsilon4 genotype (n=19) showed a non-significantly greater T2-LL (16.0 (SD 14.0) cm(3)) than patients with the epsilon2/epsilon3 (n=11; 13.3 (9.5) cm(3)) or the epsilon3/epsilon3 genotype (n=49; 9.4 (SD 9.2) cm(3)). Both the T1-LL (2.6 (SD 3.3) v 1.6 (SD 2.4) and 1.2 (SD 3.0) cm(3); p=0.04) and the black hole ratio (14.3 SD 11.9) v 7.4 (SD 9.3) and 8.4 (SD 13.3)%; p=0.02), however, were significantly higher in epsilon3/epsilon4 patients. Similar differences were seen when comparing patients with at least one epsilon4 allele with the remainder of the group.
CONCLUSIONS: These data support speculations on a modulation of multiple sclerosis severity by the apoE genotype which can be attributed to more extensive tissue destruction or less efficient repair in carriers of the epsilon4 allele.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864599      PMCID: PMC1737030          DOI: 10.1136/jnnp.69.1.25

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

1.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

2.  Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group.

Authors:  A D Sadovnick; G C Ebers; D A Dyment; N J Risch
Journal:  Lancet       Date:  1996-06-22       Impact factor: 79.321

3.  Impairment and recovery of ipsilateral sensory-motor function following unilateral cerebral infarction.

Authors:  R D Jones; I M Donaldson; P J Parkin
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

Review 4.  The epidemiology of multiple sclerosis: a general overview.

Authors:  C M Poser
Journal:  Ann Neurol       Date:  1994-12       Impact factor: 10.422

5.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

6.  Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease.

Authors:  D C Rubinsztein; C S Hanlon; R M Irving; S Goodburn; D G Evans; H Kellar-Wood; J H Xuereb; O Bandmann; A E Harding
Journal:  Mol Cell Probes       Date:  1994-12       Impact factor: 2.365

7.  Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro.

Authors:  B P Nathan; S Bellosta; D A Sanan; K H Weisgraber; R W Mahley; R E Pitas
Journal:  Science       Date:  1994-05-06       Impact factor: 47.728

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

9.  A role for apolipoprotein E, apolipoprotein A-I, and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve.

Authors:  J K Boyles; C D Zoellner; L J Anderson; L M Kosik; R E Pitas; K H Weisgraber; D Y Hui; R W Mahley; P J Gebicke-Haerter; M J Ignatius
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

10.  Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images.

Authors:  M A van Walderveen; F Barkhof; O R Hommes; C H Polman; H Tobi; S T Frequin; J Valk
Journal:  Neurology       Date:  1995-09       Impact factor: 9.910

View more
  12 in total

1.  Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord.

Authors:  Tong Liu; K Christian Donahue; Jun Hu; Michael P Kurnellas; Jennifer E Grant; Hong Li; Stella Elkabes
Journal:  J Proteome Res       Date:  2007-06-16       Impact factor: 4.466

2.  Crystallization and preliminary X-ray diffraction analysis of apolipoprotein E-containing lipoprotein particles.

Authors:  Yvonne Newhouse; Clare Peters-Libeu; Karl H Weisgraber
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-10-20

3.  Magnetisation transfer ratio analysis of normal appearing white matter in patients with familial and sporadic multiple sclerosis.

Authors:  M Siger-Zajdel; K Selmaj
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-12       Impact factor: 10.154

Review 4.  Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  J Med Chem       Date:  2012-10-05       Impact factor: 7.446

5.  A second-generation genomic screen for multiple sclerosis.

Authors:  S J Kenealy; M-C Babron; Y Bradford; N Schnetz-Boutaud; J L Haines; J B Rimmler; S Schmidt; M A Pericak-Vance; L F Barcellos; R R Lincoln; J R Oksenberg; S L Hauser; M Clanet; D Brassat; G Edan; J Yaouanq; G Semana; I Cournu-Rebeix; O Lyon-Caen; B Fontaine
Journal:  Am J Hum Genet       Date:  2004-10-19       Impact factor: 11.025

6.  Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis.

Authors:  Silke Schmidt; Lisa F Barcellos; Karen DeSombre; Jacqueline B Rimmler; Robin R Lincoln; Patricia Bucher; Ann M Saunders; Eric Lai; Eden R Martin; Jeffery M Vance; Jorge R Oksenberg; Stephen L Hauser; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Am J Hum Genet       Date:  2002-02-11       Impact factor: 11.025

Review 7.  The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Hong-Liang Zhang; Jiang Wu; Jie Zhu
Journal:  Clin Dev Immunol       Date:  2010-05-31

8.  Apolipoprotein E as a novel therapeutic neuroprotection target after traumatic spinal cord injury.

Authors:  Xiaoxin Cheng; Yiyan Zheng; Ping Bu; Xiangbei Qi; Chunling Fan; Fengqiao Li; Dong H Kim; Qilin Cao
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

Review 9.  Aging, neurodegenerative disease, and traumatic brain injury: the role of neuroimaging.

Authors:  Carrie Esopenko; Brian Levine
Journal:  J Neurotrauma       Date:  2014-12-29       Impact factor: 5.269

10.  Microstructural tissue damage in normal appearing brain tissue accumulates with Framingham Stroke Risk Profile Score: magnetization transfer imaging results of the Austrian Stroke Prevention Study.

Authors:  Nina Homayoon; Stefan Ropele; Edith Hofer; Petra Schwingenschuh; Stephan Seiler; Reinhold Schmidt
Journal:  Clin Neurol Neurosurg       Date:  2013-01-06       Impact factor: 1.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.